Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.

Int J Health Policy Manag · 2024 · PMC11270615 · PMID 38618837

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significanceP = .057so close (0.05 < p ≤ 0.1)

While domestically developed indications seemed more likely to be reimbursed in the univariate analysis (HR = 3.49, 95% CI: 1.27–9.63, P = .016), this effect did not reach statistical significance in the multivariate regression analysis (HR = 3.45, 95% CI: 0.97–12.35, P = .057).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.